BioDlink Biopharm Co Ltd, a China-based global contract development and manufacturing organisation (CDMO), announced on Friday that it recently hosted its 2025 Peer Advisory Board, spotlighting China's clinical trial and CDMO landscape as a global springboard for biotech innovation.
At this event, themed 'Advancing Innovative Drugs Together Worldwide', BioDlink, alongside partners BioPlus, Cobetter, NanoMicro Technology, and Hengyu Biotech, convened top biotech CEOs, MNC executives, research leaders and investment management to discuss how innovative biotech companies could leverage China's rapidly evolving clinical trial and CDMO ecosystem.
Backed by 15 years of operational experience, BioDlink says that it combines advanced biologics development and manufacturing capabilities with a synergistic industrial ecosystem. It also enables biotech companies to fast-track clinical programmes, optimise development budgets, and undertake global regulatory filings while complying with global quality standards.
This event also marked the official launch of BioDlink's English-language brand, with 'Bio' representing biopharma excellence in large molecules; 'D' representing drug-driven and innovation-focused, specialising in ADC/XDC development and manufacturing, and honouring its legacy with a capitalised first letter of 'Dongyao'; and 'link' representing precise bioconjugation and linker technology to connect the world to a BioDlink-centric ecosystem.
Tyra Biosciences to announce TYRA-300 preclinical results at ENDO 2025
Centivax raises USD45m to commercialise universal flu vaccine
Adcentrx Therapeutics' ADRX-0405 granted US FDA orphan drug designation
Avenzo Therapeutics doses first patient in AVZO-1418/DB-1418 Phase 1/2 clinical study
SCG Cell's SCG101V therapy Investigational New Drug Application receives Chinese regulatory approval
KalVista secures FDA approval for EKTERLY, first oral on-demand HAE treatment
BioDlink convenes peer advisory event on innovation and collaboration strategies
CyanVac's nasal COVID vaccine shows promise in phase 1 trial
Imfinzi approved in EU as first perioperative immunotherapy for muscle-invasive bladder cancer
Akeso's bispecific ADC (Trop2/Nectin4 ADC) enters clinical trials
Brii Biosciences enters BRII-693 licensing agreement with Joincare Group in Greater China
Neurizon enters global license agreement with Elanco to commercialise NUZ-001
Ascletis doses first US participants in ASC30 Phase IIa study for obesity treatment
Jacobio's JAB-8263 Phase I/II Clinical Trial IND application receives Chinese regulatory approval